CERO Therapeutics shareholders approve 1:20 reverse stock split, increase share reserve by 2M shares

CERO THERAPEUTICS HOLDINGS, INC.

Reverse stock split ratio set at 1:20, effective 12:01 a.m. ET on June 10, 2025, subject to regulatory processes.
Shareholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 2,000,000 shares.
Election of Class I directors Michael Byrnes and Lindsey Rolfe, M.D. to serve until 2028 annual meeting.
Ratification of Wolf & Company, P.C. as independent registered public accounting firm for fiscal year 2025.
Also approved issuance of shares upon exercise of February 2025 warrants and conversion of Series D preferred below market price.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.